Valuation: Theralase Technologies Inc.

Market Cap 84.27M 60.07M 52.22M 48.6M 44.62M 5.73B 85.57M 573M 225M 2.85B 226M 221M 9.57B P/E 2026 *
-28.5x
P/E 2027 * 14.3x
Enterprise Value 84.27M 60.07M 52.22M 48.6M 44.62M 5.73B 85.57M 573M 225M 2.85B 226M 221M 9.57B EV / Sales 2026 *
105x
EV / Sales 2027 * 2.49x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day+1.79%
1 week+7.55%
1 month+11.76%
3 months-10.94%
6 months+14.00%
Current year+72.73%
1 week 0.26
Extreme 0.26
0.29
1 month 0.25
Extreme 0.25
0.29
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 2023-06-28
Director of Finance/CFO - 2019-06-26
Chief Executive Officer - 2021-11-14
Director TitleAgeSince
Chairman - -
Director/Board Member - 2007-12-31
Director/Board Member - 2019-06-26
Date Insider Type Main position Quantity % Market Cap.
5/20/26 Buy

Director

20,900 0.0081%
5/20/26 Option

Chief Financial Officer

11,000 0.0043%
7/31/25 Sell

Chief Financial Officer

130,000 0.0525%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%+7.55%+35.71%-.--% 60.07M
-1.33%-0.45%+33.16%+44.02% 1.43B
-3.67%-1.41%-13.93%-51.05% 51.32M
Average -1.07%+1.90%+18.31%-2.34% 514.72M
Weighted average by Cap. -1.29%-0.17%+31.70%+39.15%

Financials

2026 *2027 *
Net sales 802K 572K 497K 463K 425K 54.57M 814K 5.45M 2.14M 27.17M 2.15M 2.1M 91.1M 33.89M 24.16M 21M 19.55M 17.95M 2.31B 34.41M 230M 90.42M 1.15B 90.72M 88.73M 3.85B
Net income -4.2M -2.99M -2.6M -2.42M -2.22M -286M -4.27M -28.55M -11.21M -142M -11.24M -11M -477M 6.83M 4.87M 4.23M 3.94M 3.62M 465M 6.94M 46.44M 18.23M 231M 18.29M 17.89M 776M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
26-07-31 $0.2850 +1.79% 152,151
26-07-30 $0.2800 +3.70% 110,511
26-07-29 $0.2700 -.--% 223,068
26-07-28 $0.2700 +3.85% 43,002
26-07-27 $0.2600 -1.89% 18,519
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2850CAD
Average target price
0.7000CAD
Spread / Average Target
+145.61%

Quarterly revenue - Rate of surprise